5th Gene Therapy for Ophthalmic Disorders Summit
Evvnt Promotion / evvnt
Archivio
10.09.2024 - 12.09.2024 Wyndham Boston Beacon Hill, 5 Blossom Street, 02114 Boston, Massachusetts, USA
Time: 8:00 AM - 5:00 PM
Temi della conferenza
Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.
Ophthalmic drug developers are unlocking the full potential of gene therapy. Crucial lessons learnt from both clinical successes and failures, coupled with recent improvements in development and delivery, means that the space is poised to capitalize on the significant potential of the eye as a target for genetic medicine approaches.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Annotazioni
URL:
Brochure: https://go.evvnt.com/2478440-2?pid=4832
Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President - Protein Sciences, Spotlight Therapeutics, and more
URL:
Brochure: https://go.evvnt.com/2478440-2?pid=4832
Speakers: Abraham Scaria, Chief Scientific Officer, Beacon Therapeutics, Adam Silverman, Vice President - Protein Sciences, Spotlight Therapeutics, and more
Informazioni ed Iscrizioni:
https://go.evvnt.com/2478440-3?pid=4832
Ms. Mara Mihailovic
Medicina General
Contatto organizzatori
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Noi, Going International, siamo un’azienda che si è scelta come obiettivo di rendere acessibile la formazione a una grandissima quantità di persone, oltrepassanddo i confini geografici e sociali."
